Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: Findings from a Veterans Affairs–based population

Efectos adversos metabólicos y endocrinos de los antipsicóticos de segunda generación en niños y adolescentes: una revisión sistemática de ensayos aleatorizados, controlados con placebo y guías de práctica clínica

“…Pero la evaluación de los métodos de detección aplicados por los clínicos muestra de manera constante que estos métodos son subóptimos 13,62,66,[89][90][91]95,97 . La baja tasa de uso de pruebas de detección ha sido confirmada también recientemente en niños tratados con antipsicóticos 92 , a pesar de que existe un consenso respecto a que está justificado el examen de detección y la monitorización de los efectos secundarios.…”

Current and Projected Characteristics and Unique Health Care Needs of the Patient Population Served by the Department of Veterans Affairs

“…Algorithm not validated but used in Hsu et al (2008) study of VA mental health. We excluded ICD-9 codes for non-specific psychosis to avoid using episodes of psychosis not associated with schizophrenia, such as 289.9 (pyschosis not otherwise specified).…”

Lipid profile screening in second-generation antipsychotic users: the gap between policy and practice

“…The Consensus Statement specifically recommended that fasting lipids be assessed at baseline and monitored regularly. Numerous studies, from before and after the Consensus Statement and involving a variety of commercially insured [27,28], Medicaid [29,30] and Veteran Affairs [31] populations from the USA, have consistently shown that on average, less than one-fifth of patients taking SGAs receive baseline lipid testing and less than one half receive ongoing lipid monitoring. Background lipid screening rates have been gradually increasing in the USA; however, drug-related lipid testing for patients taking SGAs does not appear to have increased meaningfully as a result of the Consensus Statement.…”

“…Rather, lipid testing among antipsychotic users appears to be more closely correlated with the age of the patient, consistent with general public health screening guidelines [32]; that is, rates are lowest in children and highest in adults older than 40 years. Moreover, lipid testing is generally two-to three-times more likely to occur if the patient has pre-existing dyslipidemia [30,31]. In other words, the majority of lipid testing asso ciated with antipsychotic use involves monitoring future science group Lipid profile screening in second-generation antipsychotic users | Editorial patients already diagnosed and being treated for dyslipidemia rather than screening patients to identify unrecognized disease.…”